Sentences with word «nilotinib»

Also, Georgetown holds an issued US patent on related technology for the use of nilotinib for the treatment of certain neurodegenerative diseases and has other pending patent applications in US and foreign jurisdictions.

Moussa is an inventor on a Georgetown University patent application for use of nilotinib for the treatment of neurodegenerative disease.

GUMC says its researchers are now planning larger clinical trials with nilotinib for patients with Parkinson's and other similar diseases including Alzheimer's disease, likely to begin in 2016.

Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition.

Before nilotinib, he was unable to do simple household tasks, but after the trial he said, «Now, I empty the garbage, unload the dishwasher, load the washer and the dryer, set the table, even take responsibility for grilling.»

Before taking nilotinib, he said he didn't do much around the house.

A study unveiled at the Society for Neuroscience's annual meeting found that 11 patients with Parkinson's disease with dementia who were given nilotinib, an FDA - approved drug for leukemia that's sold by Novartis as Tasigna, experienced improved cognition, motor skills and non-motor function in a 12 - patient, six - month trial.

One such agent nilotinib (Tasigna ® by Novartis), used to treat leukemia, is being studied in patients with Parkinson's and Alzheimer's diseases.

This work has led to clinical trials with the cancer drug nilotinib in both Parkinson's and Alzheimer's disease set to begin this summer.

The adenosine triphosphate (ATP)-- competitive kinase inhibitors imatinib (STI571; trade name: Gleevec), dasatinib, and nilotinib inhibit multiple tyrosine kinases in addition to ABL1 and ABL2 (5).

In the proof of concept study, 12 patients received nilotinib, an FDA - approved drug for leukemia.

Moussa and other Georgetown researchers are planning larger clinical trials with nilotinib for patients with Parkinson's and other similar diseases including Alzheimer's disease, likely to begin this year.

[70] Additionally, our phase II study of nilotinib in melanomas refractory or intolerant to a prior KIT inhibitor found partial responses in 18 % of patients and disease control for 4 months in 27 %.

Moussa conducted the preclinical research that led to the discovery of nilotinib for the treatment of neuro - degenerative diseases, then partnered with Pagan for the clinical study.

Pagan said that a larger, more comprehensive study must be done before determining the drug's true impact, but if the drug's effectiveness is confirmed in such tests, nilotinib could become the first treatment to impede the killing of brain cells that's consistent with Parkinson's, according to NPR.

«Although TKIs such as the first - generation TKI imatinib mesylate (IM) and the second - generation TKIs dasatinib and nilotinib have markedly improved the prognosis of patients with chronic phase CML, a cure remains elusive.

(Moussa is listed as an inventor on a patent application that Georgetown University filed related to nilotinib and the use of other tyrosine kinase inhibitors for the treatment of neurodegenerative diseases.)

New inhibitors include dasatinib and nilotinib, which are significantly more potent than imatinib and may overcome resistance.

CML patients treated with nilotinib had fewer treatment - emergent BCR - ABL mutations than those treated with imatinib, and among patients who did have a mutation, those treated with nilotinib had reduced rates of progression to accelerated phase and blast phase of the disease.

«To say that nilotinib has made a change in our lives is a huge understatement.»

Investigators report that the six - month study of nilotinib, a treatment for chronic myelogenous leukemia or CML, produced benefit for all study patients who completed the trial (11 of 12), with 11 patients reporting meaningful clinical improvements.

Researchers say that use of nilotinib, in doses much smaller than those used to treat cancer, was welltolerated with no serious side effects.

Druker said that Gleevec's long - term efficacy also offers a benchmark for comparative testing of two other similar kinase inhibitors, dasatinib and nilotinib, now underway.

«If dasatinib or nilotinib can beat Gleevec in the response they elicit, they will offer patients even greater protection from relapse and possibly even better survival,» he said.

Also, nilotinib was not compared with a placebo or other medications used to treat Parkinson's in the study.

In a significant, yet unusual judgment the Court of Justice of the European Union (CJEU) upheld the General Court's decision (T - 140 / 12; Teva Pharma v. EMA) that had affirmed the European Medicines Agency's (EMA) rejection of Teva's generic drug application for Glivec ® (active substance - imatinib), not due to the reference product's own orphan drug exclusivity but in view of orphan drug exclusivity of a similar medicinal product — Tasigna ® (active substance - nilotinib).

Citing a hypothetical scenario, Teva claimed that if marketing authorization for nilotinib was granted in November 2011, then the interpretation adopted by EMA would have prevented imatinib generic filings until November 2021, i.e. for twenty years from its first marketing authorization date.

However, the General Court upheld the EMA's decision refusing Teva's generic application for imatinib in view of nilotinib's orphan drug exclusivity pertaining to CML.

In November 2007 another Novartis drug, Tasigna ® (nilotinib), was submitted for marketing authorization for CML, but since it was found to be structurally similar to imatinib by the EMA, Novartis was obligated to obtain consent from the first marketing authorization holder under Article 8 (3)(a) of the Orphan Drugs Regulation due to the existing orphan exclusivity of imatinib.

Thus, in view of the similarity of Teva's generic product to that of nilotinib and its orphan exclusivity the General Court validated the EMA's rejection of Teva's generic drug application.